EphB3 Antagonist Antibodies Receptor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective compositions and treatments for modulating EphB3 receptor activity, which is implicated in various diseases such as coeliac disease, neurodegenerative disorders, and angiogenic diseases, and there is a need for specific antagonist antibodies to manage these conditions.
Innovation Solution
Development of EphB3 antagonist antibodies with high affinity that bind to the extracellular domain of EphB3, competing with existing antibodies and inhibiting receptor activation, dimerization, and phosphorylation, thereby modulating EphB3-mediated processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EphB3 antagonist antibodies are developed to inhibit receptor activity, then therapeutic benefits are achieved in treating EphB3-related diseases, but the complexity of identifying and characterizing specific high-affinity antibodies increases
Solution Approach 1:
The patent applies preliminary action by pre-selecting and characterizing a panel of candidate antibodies (including XPA.04.017, XHA.05.172, XHA.05.849, XPA.04.031, and XPA.04.019) with known binding properties before clinical application. This preliminary characterization of antibody affinity, epitope specificity, and functional activity streamlines the selection process and reduces the complexity of identifying suitable therapeutic candidates.
Solution Approach 2:
The patent employs parameter changes by systematically evaluating antibodies based on multiple parameters including binding affinity (KD values), epitope location, and functional activity. By establishing quantitative criteria for antibody selection and optimization, the patent transforms the complex qualitative process of antibody characterization into a systematic parameter-based approach that facilitates identification of high-affinity antagonists.
2Reliability
If high-affinity antagonist antibodies are used to compete with existing antibodies for binding to EphB3, then receptor activation is effectively inhibited, but the specificity requirements for antibody design become more stringent
Solution Approach 1:
The patent applies local quality by focusing antibody design and selection on specific epitope regions of the EphB3 extracellular domain. By identifying and targeting particular local regions (epitopes) rather than the entire receptor surface, the patent achieves high-specificity binding that effectively blocks receptor activation while maintaining clear discrimination between target and non-target molecules.
Solution Approach 2:
The patent uses intermediary approaches by employing a panel of antibodies with different epitope specificities as mediators to study EphB3 function and regulation. These intermediary antibodies serve as tools to probe different aspects of receptor activity, allowing researchers to understand EphB3 biology while identifying the most effective therapeutic candidates.
3Object-affected harmful factors
If antagonist antibodies inhibit EphB3-mediated processes such as cell proliferation and angiogenesis, then pathological conditions are addressed, but the potential impact on normal physiological functions requiring EphB3 activity must be considered
Solution Approach 1:
The patent applies partial action by using antagonist antibodies at controlled doses and durations to inhibit EphB3 activity only to the extent necessary for therapeutic effect. By implementing dose-dependent inhibition rather than complete blockade, the patent can address pathological conditions (such as abnormal cell proliferation or angiogenesis) while preserving sufficient EphB3 activity for normal physiological functions.
Solution Approach 2:
The patent employs dynamics by designing treatment regimens that allow EphB3 activity to be dynamically regulated rather than statically blocked. The use of reversible antibody binding and adjustable dosing schedules enables the system to adapt EphB3 inhibition levels to match therapeutic needs while preserving physiological adaptability for normal cellular processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EphB3 antagonist antibodies effectively reduce EphB3 receptor activity, providing therapeutic benefits in treating EphB3-related diseases by inhibiting cell proliferation, promoting neural regeneration, and addressing pathological conditions in intestinal and vascular systems.
Implementation Method 1
EphB3 antagonist antibodies with high affinity that bind to the extracellular domain of EphB3, competing with existing antibodies and inhibiting receptor activation, dimerization, and phosphorylation
Data Source
AI summary
EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.